Synopsis
Synopsis
0
EU WC
0
VMF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Hydrochloride, Pilocarpine
2. Isopilocarpine
3. Isoptocarpine
4. Nitrate, Pilocarpine
5. Ocusert
6. Pilocarpine
7. Pilocarpine Mononitrate, (3s-cis)-isomer
8. Pilocarpine Nitrate
9. Pilocarpine, Monohydrochloride, (3s-cis)-isomer
10. Salagen
1. 54-71-7
2. (+)-pilocarpine Hydrochloride
3. Pilocarpine Hcl
4. Almocarpine
5. Salagen
6. Adsorbocarpine
7. Pilocarpal
8. Pilocar
9. Pilocar Smp
10. Pilocarpine Monohydrochloride
11. Pilomiotin
12. Pilovisc
13. Pilocel
14. Sno Pilo
15. Mistura P
16. Pilocarpine Muriate
17. Epicar
18. Mi-pilo Ophth Sol
19. Pilopine Hs
20. Vistacarpin N
21. Pilocarpine, Hydrochloride
22. Spersacarpine Hydrochloride
23. Pilokarpin Monohydrochloride
24. Pilopine
25. Pilocarpine Chloride
26. Pilocarpine (hydrochloride)
27. Pilo
28. Pilocarpinum Muriaticum
29. Pilocarpine, Monohydrochloride
30. Pilocarpine Hydrochlororide
31. Mls000069454
32. 0ww6d218xj
33. Isoptocarpine
34. (3s,4r)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one;hydrochloride
35. Nsc5746
36. Smr000059053
37. Isopto Carpine
38. Isopto-carpine
39. Ami-pilo
40. Amistura P
41. 2(3h)-furanone, 3-ethyldihydro-4-((1-methyl-1h-imidazol-5-yl)methyl)-, Monohydrochloride, (3s,4r)-
42. 2(3h)-furanone, 3-ethyldihydro-4-((1-methyl-1h-imidazol-5-yl)methyl)-, Monohydrochloride, (3s-cis)-
43. Pilopine Hs Gel
44. Nsc 5746
45. (3s,4r)-3-ethyl-4-((1-methyl-1h-imidazol-5-yl)methyl)dihydrofuran-2(3h)-one Hydrochloride
46. (3s,4r)-3-ethyl-4-[(1-methyl-1h-imidazol-5-yl)methyl]dihydrofuran-2(3h)-one Hydrochloride
47. Einecs 200-212-5
48. Unii-0ww6d218xj
49. Pilocarpine-hcl
50. Ai3-61859
51. Sr-01000000054
52. Mi-pilo
53. Component Of Epicar
54. Salagen (tn)
55. Sanpilo (tn)
56. Component Of Pilocar
57. Pilocarpine Hydrochloride [usp:jan]
58. Vuity
59. Pilopine Hs (tn)
60. Isopto Carpine (tn)
61. Nsc-5746
62. Pilocarpini Hydrochloridum
63. Regid855931
64. Opera_id_1616
65. Schembl41427
66. Mls000758210
67. Mls001076314
68. Mls001424017
69. Nsc 5746 Hcl
70. Pilocarpine Hcl [vandf]
71. Chembl1200330
72. Dtxsid2041096
73. Chebi:141029
74. Hy-b0726
75. Tox21_500950
76. S4231
77. Pilocarpine Hydrochloride [mi]
78. Pilocarpinum Muriaticum [hpus]
79. Akos005267231
80. Pilocarpine Hydrochloride (jp17/usp)
81. Ccg-100757
82. Lp00950
83. Nc00007
84. Pilocarpine Hydrochloride [jan]
85. (3s,4r)-3-ethyl-4-[(1-methylimidazol-5-yl)methyl]-3,4,5-trihydrofuran-2-one, C Hloride
86. Ncgc00094254-01
87. Ncgc00261635-01
88. Pilocarpine Hydrochloride [mart.]
89. Pilocarpine Hydrochloride [vandf]
90. Ac-33119
91. Pilocarpine Hydrochloride [usp-rs]
92. Pilocarpine Hydrochloride [who-dd]
93. Pilocarpine Hydrochloride [who-ip]
94. Eu-0100950
95. Sw196587-4
96. D02200
97. D91961
98. P 6503
99. Pilocarpine Hydrochloride [ep Impurity]
100. Pilocarpine Hydrochloride [ep Monograph]
101. Pilocarpine Hydrochloride [orange Book]
102. Pilocarpine Hydrochloride [usp Impurity]
103. 2(3h)-furanone, Monohydrochloride, (3s-cis)-
104. Pilocarpine Hydrochloride [usp Monograph]
105. Pilocarpini Hydrochloridum [who-ip Latin]
106. Wln: T5ovtj C2 D1- Dt5n Cnj C1 &gh
107. Sr-01000000054-3
108. Sr-01000075339-1
109. Pilocarpine Hydrochloride, >=98% (titration), Powder
110. Q23059847
111. Betoptic Pilo Component Pilocarpine Hydrochloride
112. Pilocarpine Hydrochloride Component Of Betoptic Pilo
113. Pilocarpine Hydrochloride, Meets Usp Testing Specifications
114. Pilocarpine Hydrochloride, European Pharmacopoeia (ep) Reference Standard
115. (3s,4r)-3-ethyl-4-[(1-methyl-1h-imidazol-5-yl)methyl]oxolan-2-one Hydrochloride
116. Pilocarpine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
117. Pilocarpine Hydrochloride, United States Pharmacopeia (usp) Reference Standard
118. (3s-cis)-3-ethyldihydro-4-[(1-methyl-1h-imidazol-5-yl)methyl]-2(3h)-furanone Hydrochloride
119. 2(3h)-furanone, 3-ethyldihydro-4-((1-methyl-1h-imidazol-5-yl)methyl)-, Hydrochloride (1:1), (3s,4r)-
Molecular Weight | 244.72 g/mol |
---|---|
Molecular Formula | C11H17ClN2O2 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 3 |
Exact Mass | 244.0978555 g/mol |
Monoisotopic Mass | 244.0978555 g/mol |
Topological Polar Surface Area | 44.1 Ų |
Heavy Atom Count | 16 |
Formal Charge | 0 |
Complexity | 245 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 8 | |
---|---|
Drug Name | Isopto carpine |
PubMed Health | Pilocarpine |
Drug Classes | Dental Agent, Direct Acting Miotic |
Drug Label | Isopto Carpine (pilocarpine hydrochloride ophthalmic solution) is a cholinergic agonist prepared as a sterile topical ophthalmic solution. The active ingredient is represented by the chemical structure:Established name: pilocarpine hydrochlorideChe... |
Active Ingredient | Pilocarpine hydrochloride |
Dosage Form | Solution |
Route | Ophthalmic |
Strength | 1%; 2%; 4% |
Market Status | Prescription |
Company | Alcon Res |
2 of 8 | |
---|---|
Drug Name | Pilocarpine hydrochloride |
PubMed Health | Pilocarpine |
Drug Classes | Dental Agent, Direct Acting Miotic |
Drug Label | Pilocarpine hydrochloride tablets contain pilocarpine hydrochloride, a cholinergic agonist for oral use. Pilocarpine hydrochloride is a hygroscopic, odorless, bitter tasting white crystal or powder, which is soluble in water and alcohol and virtually... |
Active Ingredient | Pilocarpine hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 7.5mg; 5mg |
Market Status | Prescription |
Company | Corepharma; Roxane; Lannett; Impax Labs |
3 of 8 | |
---|---|
Drug Name | Pilopine hs |
Drug Label | SALAGEN Tablets contain pilocarpine hydrochloride, a cholinergic agonist for oral use. Pilocarpine hydrochloride is a hygroscopic, odorless, bitter tasting white crystal or powder which is soluble in water and alcohol and virtually insoluble in mos... |
Active Ingredient | Pilocarpine hydrochloride |
Dosage Form | Gel |
Route | Ophthalmic |
Strength | 4% |
Market Status | Prescription |
Company | Alcon |
4 of 8 | |
---|---|
Drug Name | Salagen |
Active Ingredient | Pilocarpine hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 7.5mg; 5mg |
Market Status | Prescription |
Company | Eisai |
5 of 8 | |
---|---|
Drug Name | Isopto carpine |
PubMed Health | Pilocarpine |
Drug Classes | Dental Agent, Direct Acting Miotic |
Drug Label | Isopto Carpine (pilocarpine hydrochloride ophthalmic solution) is a cholinergic agonist prepared as a sterile topical ophthalmic solution. The active ingredient is represented by the chemical structure:Established name: pilocarpine hydrochlorideChe... |
Active Ingredient | Pilocarpine hydrochloride |
Dosage Form | Solution |
Route | Ophthalmic |
Strength | 1%; 2%; 4% |
Market Status | Prescription |
Company | Alcon Res |
6 of 8 | |
---|---|
Drug Name | Pilocarpine hydrochloride |
PubMed Health | Pilocarpine |
Drug Classes | Dental Agent, Direct Acting Miotic |
Drug Label | Pilocarpine hydrochloride tablets contain pilocarpine hydrochloride, a cholinergic agonist for oral use. Pilocarpine hydrochloride is a hygroscopic, odorless, bitter tasting white crystal or powder, which is soluble in water and alcohol and virtually... |
Active Ingredient | Pilocarpine hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 7.5mg; 5mg |
Market Status | Prescription |
Company | Corepharma; Roxane; Lannett; Impax Labs |
7 of 8 | |
---|---|
Drug Name | Pilopine hs |
Drug Label | SALAGEN Tablets contain pilocarpine hydrochloride, a cholinergic agonist for oral use. Pilocarpine hydrochloride is a hygroscopic, odorless, bitter tasting white crystal or powder which is soluble in water and alcohol and virtually insoluble in mos... |
Active Ingredient | Pilocarpine hydrochloride |
Dosage Form | Gel |
Route | Ophthalmic |
Strength | 4% |
Market Status | Prescription |
Company | Alcon |
8 of 8 | |
---|---|
Drug Name | Salagen |
Active Ingredient | Pilocarpine hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 7.5mg; 5mg |
Market Status | Prescription |
Company | Eisai |
Muscarinic Agonists
Drugs that bind to and activate muscarinic cholinergic receptors (RECEPTORS, MUSCARINIC). Muscarinic agonists are most commonly used when it is desirable to increase smooth muscle tone, especially in the GI tract, urinary bladder and the eye. They may also be used to reduce heart rate. (See all compounds classified as Muscarinic Agonists.)
Miotics
Agents causing contraction of the pupil of the eye. Some sources use the term miotics only for the parasympathomimetics but any drug used to induce miosis is included here. (See all compounds classified as Miotics.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
In the VIRGO trial evaluating twice-daily administration of VUITY (pilocarpine HCl ophthalmic solution), the primary endpoint of improving near vision without compromising distance vision at Day 14, Hour 9 was met.
Lead Product(s): Pilocarpine Hydrochloride
Therapeutic Area: Ophthalmology Brand Name: Vuity
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2022
Lead Product(s) : Pilocarpine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In the VIRGO trial evaluating twice-daily administration of VUITY (pilocarpine HCl ophthalmic solution), the primary endpoint of improving near vision without compromising distance vision at Day 14, Hour 9 was met.
Brand Name : Vuity
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 05, 2022
Details:
FDA approval of VUITY (Pilocarpine), is a once-daily prescription eye drop that improves near and intermediate vision without impacting distance vision for adults with age-related blurry near vision.
Lead Product(s): Pilocarpine Hydrochloride
Therapeutic Area: Ophthalmology Brand Name: Vuity
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2021
Lead Product(s) : Pilocarpine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
VUITY™ (Pilocarpine HCI Ophthalmic Solution) 1.25%, the First and Only FDA-Approved Eye Drop to ...
Details : FDA approval of VUITY (Pilocarpine), is a once-daily prescription eye drop that improves near and intermediate vision without impacting distance vision for adults with age-related blurry near vision.
Brand Name : Vuity
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 09, 2021
Details:
VUITY, an optimized formulation of pilocarpine, established eye care therapeutic, specifically designed to treat age-related blurry near vision. It is delivered with proprietary pHast™ technology, which allows VUITY to rapidly adjust to physiologic pH of the tear film.
Lead Product(s): Pilocarpine Hydrochloride
Therapeutic Area: Ophthalmology Brand Name: Vuity
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Lead Product(s) : Pilocarpine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VUITY, an optimized formulation of pilocarpine, established eye care therapeutic, specifically designed to treat age-related blurry near vision. It is delivered with proprietary pHast™ technology, which allows VUITY to rapidly adjust to physiologic pH ...
Brand Name : Vuity
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 28, 2022
Details:
VUITY is an optimized formulation of pilocarpine, an established eye care therapeutic, specifically designed to treat age-related blurry near vision. It is delivered with proprietary pHas technology, which allows VUITY to rapidly adjust to physiologic pH of the tear film.
Lead Product(s): Pilocarpine Hydrochloride
Therapeutic Area: Ophthalmology Brand Name: Vuity
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Lead Product(s) : Pilocarpine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VUITY is an optimized formulation of pilocarpine, an established eye care therapeutic, specifically designed to treat age-related blurry near vision. It is delivered with proprietary pHas technology, which allows VUITY to rapidly adjust to physiologic pH...
Brand Name : Vuity
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 19, 2022
Details:
VUITY™ (pilocarpine HCL ophthalmic solution) 1.25% is a prescription eyedrop to treat age-related blurry near vision (presbyopia) in adults. VUITY to improve near and intermediate vision without impacting distance vision with one drop daily.
Lead Product(s): Pilocarpine Hydrochloride
Therapeutic Area: Ophthalmology Brand Name: Vuity
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2021
Lead Product(s) : Pilocarpine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
U.S. Food and Drug Administration Approves VUITY™ (Pilocarpine HCI Ophthalmic Solution) 1.25%, t...
Details : VUITY™ (pilocarpine HCL ophthalmic solution) 1.25% is a prescription eyedrop to treat age-related blurry near vision (presbyopia) in adults. VUITY to improve near and intermediate vision without impacting distance vision with one drop daily.
Brand Name : Vuity
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 29, 2021
Details:
The company will present patient-reported outcomes for AGN-190584, an investigational therapy for the treatment of presbyopia. Recently the company submitted an NDA to the U.S. Food and Drug Administration based on data from the Phase 3 GEMINI 1 and GEMINI 2 clinical trials.
Lead Product(s): Pilocarpine Hydrochloride
Therapeutic Area: Ophthalmology Brand Name: AGN-190584
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: AbbVie Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2021
Lead Product(s) : Pilocarpine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : AbbVie Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The company will present patient-reported outcomes for AGN-190584, an investigational therapy for the treatment of presbyopia. Recently the company submitted an NDA to the U.S. Food and Drug Administration based on data from the Phase 3 GEMINI 1 and GEMI...
Brand Name : AGN-190584
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 27, 2021
Details:
Allergan has submitted a New Drug Application to the U.S. Food and Drug Administration for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. The FDA is expected to act on the NDA by the end of 2021.
Lead Product(s): Pilocarpine Hydrochloride
Therapeutic Area: Ophthalmology Brand Name: AGN-190584
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: AbbVie Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 25, 2021
Lead Product(s) : Pilocarpine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : AbbVie Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Allergan has submitted a New Drug Application to the U.S. Food and Drug Administration for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. The FDA is expected to act on the NDA by the end of 2021.
Brand Name : AGN-190584
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 25, 2021
Details:
Data presented at the meeting will include an analysis examining the safety and efficacy of DURYSTA™ and a second analysis of data from the Phase 3 ARTEMIS studies that identify different characteristics of glaucoma patients who may respond after being treated with DURYSTA™.
Lead Product(s): Pilocarpine Hydrochloride
Therapeutic Area: Ophthalmology Brand Name: AGN-190584
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2020
Lead Product(s) : Pilocarpine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Data presented at the meeting will include an analysis examining the safety and efficacy of DURYSTA™ and a second analysis of data from the Phase 3 ARTEMIS studies that identify different characteristics of glaucoma patients who may respond after being...
Brand Name : AGN-190584
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 06, 2020
Details:
Phase 3 GEMINI 1 and 2 studies evaluating AGN-190584 (pilocarpine 1.25%) ophthalmic solution met the primary endpoint, reaching statistical significance in improvement in near vision.
Lead Product(s): Pilocarpine Hydrochloride
Therapeutic Area: Ophthalmology Brand Name: AGN-190584
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: AbbVie Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2020
Lead Product(s) : Pilocarpine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : AbbVie Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Phase 3 GEMINI 1 and 2 studies evaluating AGN-190584 (pilocarpine 1.25%) ophthalmic solution met the primary endpoint, reaching statistical significance in improvement in near vision.
Brand Name : AGN-190584
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 28, 2020
Details:
Under the license agreement, Orasis grants Optus the rights to commercialize, import and sell Qlosi (pilocarpine hcl), a novel corrective eye drop for the treatment of presbyopia in adults, in Korea.
Lead Product(s): Pilocarpine Hydrochloride
Therapeutic Area: Ophthalmology Brand Name: Qlosi
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Optus Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 16, 2024
Lead Product(s) : Pilocarpine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Optus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Orasis Pharmaceuticals and Optus Partner to Commercialize Qlosi™ in Korea
Details : Under the license agreement, Orasis grants Optus the rights to commercialize, import and sell Qlosi (pilocarpine hcl), a novel corrective eye drop for the treatment of presbyopia in adults, in Korea.
Brand Name : Qlosi
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 16, 2024
Regulatory Info :
Registration Country : Canada
Brand Name : SALAGEN
Dosage Form : TABLET
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number : 2216345
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : JAMP PILOCARPINE
Dosage Form : TABLET
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number : 2509571
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : M-PILOCARPINE
Dosage Form : TABLET
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number : 2496119
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : ISOPTO CARPINE
Dosage Form : LIQUID
Dosage Strength : 2%
Packaging : 15ML
Approval Date :
Application Number : 868
Regulatory Info :
Registration Country : Canada
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Pilocarpine Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pilocarpine Hydrochloride, including repackagers and relabelers. The FDA regulates Pilocarpine Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pilocarpine Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Pilocarpine Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Pilocarpine Hydrochloride supplier is an individual or a company that provides Pilocarpine Hydrochloride active pharmaceutical ingredient (API) or Pilocarpine Hydrochloride finished formulations upon request. The Pilocarpine Hydrochloride suppliers may include Pilocarpine Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Pilocarpine Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Pilocarpine Hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Pilocarpine Hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Pilocarpine Hydrochloride DMFs exist exist since differing nations have different regulations, such as Pilocarpine Hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Pilocarpine Hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Pilocarpine Hydrochloride USDMF includes data on Pilocarpine Hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Pilocarpine Hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Pilocarpine Hydrochloride suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Pilocarpine Hydrochloride Drug Master File in Japan (Pilocarpine Hydrochloride JDMF) empowers Pilocarpine Hydrochloride API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Pilocarpine Hydrochloride JDMF during the approval evaluation for pharmaceutical products. At the time of Pilocarpine Hydrochloride JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Pilocarpine Hydrochloride suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Pilocarpine Hydrochloride Drug Master File in Korea (Pilocarpine Hydrochloride KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Pilocarpine Hydrochloride. The MFDS reviews the Pilocarpine Hydrochloride KDMF as part of the drug registration process and uses the information provided in the Pilocarpine Hydrochloride KDMF to evaluate the safety and efficacy of the drug.
After submitting a Pilocarpine Hydrochloride KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Pilocarpine Hydrochloride API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Pilocarpine Hydrochloride suppliers with KDMF on PharmaCompass.
A Pilocarpine Hydrochloride CEP of the European Pharmacopoeia monograph is often referred to as a Pilocarpine Hydrochloride Certificate of Suitability (COS). The purpose of a Pilocarpine Hydrochloride CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Pilocarpine Hydrochloride EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Pilocarpine Hydrochloride to their clients by showing that a Pilocarpine Hydrochloride CEP has been issued for it. The manufacturer submits a Pilocarpine Hydrochloride CEP (COS) as part of the market authorization procedure, and it takes on the role of a Pilocarpine Hydrochloride CEP holder for the record. Additionally, the data presented in the Pilocarpine Hydrochloride CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Pilocarpine Hydrochloride DMF.
A Pilocarpine Hydrochloride CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Pilocarpine Hydrochloride CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Pilocarpine Hydrochloride suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Pilocarpine Hydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Pilocarpine Hydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Pilocarpine Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Pilocarpine Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Pilocarpine Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Pilocarpine Hydrochloride suppliers with NDC on PharmaCompass.
Pilocarpine Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Pilocarpine Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Pilocarpine Hydrochloride GMP manufacturer or Pilocarpine Hydrochloride GMP API supplier for your needs.
A Pilocarpine Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Pilocarpine Hydrochloride's compliance with Pilocarpine Hydrochloride specifications and serves as a tool for batch-level quality control.
Pilocarpine Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Pilocarpine Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Pilocarpine Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Pilocarpine Hydrochloride EP), Pilocarpine Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pilocarpine Hydrochloride USP).
LOOKING FOR A SUPPLIER?